ArticlePediatric research2025

Nirsevimab decreased the subsequent risk of respiratory syncytial virus infection and wheezing in the 2023-2024 RSV season.

Kevin Sheng-Kai Ma et al.PubMed ↗Publisher ↗

No numbers read from the abstract.